Treatment of climacteric and postmenopausal women with 17-beta-oestradiol and norethisterone acetate
- PMID: 602703
- DOI: 10.3109/00016347709154992
Treatment of climacteric and postmenopausal women with 17-beta-oestradiol and norethisterone acetate
Abstract
PIP: 3 preparations of 17beta-estradiol and norethisterone acetate were administered to 34 climacteric and 175 postmenopausal women to treat climacteric symptoms and symptoms of estrogen deficiency. 56 women were treated with trisekvens (Group 1), 131 with trisekvens forte (Group 2), and 22 with estrofem forte (Group 3). Triglycerides, cholesterol, calcium, sodium and potassium ions, alkaline phosphatase, creatinine, glucose, protein, albumin, haptoglobin, zinc sulphate, iron, TIBC, bilirubin, ALAT and ASAT, and follicle stimulating hormone (FSH), luteinizing hormone (LH), and low polar estrogens (LPE) were measured. All patients exhibited lowered S-cholesterols which reverted to normal after 6 months treatment. S-triglycerides were unchanged except in Group 1 patients where there was a slight increase after 24 months use (p .01). Serum FSH and LH decreased during treatment and this decrease was most pronounced in Groups 2 and 3. Serum LPE levels increased in Group 1, for climacteric women, to normal luteal values and in postmenopausal women to proliferation values. In groups 2 and 3, serum LPG for postmenopausal women reached luteal values. Climacteric symptoms disappeared with therapy and there was an improvement in symptoms caused by estrogen deficiency. 34 patients discontinued treatment, 14 changing to another preparation. These preparations were well tolerated with few side effects.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
